Rxsight Net Income
| RXST Stock | USD 8.21 0.05 0.61% |
As of the 11th of February 2026, Rxsight holds the Semi Deviation of 3.53, risk adjusted performance of 0.0202, and Coefficient Of Variation of 6657.58. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rxsight, as well as the relationship between them.
Rxsight Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.8704 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -24.7 M | -23.5 M | |
| Net Loss | -60.1 M | -57.1 M | |
| Net Loss | -24.7 M | -23.5 M | |
| Net Loss | (0.81) | (0.77) | |
| Net Income Per E B T | 0.90 | 0.80 |
Rxsight | Net Income | Build AI portfolio with Rxsight Stock |
The evolution of Net Income for Rxsight provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Rxsight compares to historical norms and industry peers.
Latest Rxsight's Net Income Growth Pattern
Below is the plot of the Net Income of Rxsight over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Rxsight financial statement analysis. It represents the amount of money remaining after all of Rxsight operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Rxsight's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rxsight's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (27.45 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Rxsight Net Income Regression Statistics
| Arithmetic Mean | 61,769,675 | |
| Geometric Mean | 74,761,137 | |
| Coefficient Of Variation | 131.97 | |
| Mean Deviation | 75,823,912 | |
| Median | 126,220,000 | |
| Standard Deviation | 81,515,672 | |
| Sample Variance | 6644.8T | |
| Range | 193M | |
| R-Value | (0.84) | |
| Mean Square Error | 2065.3T | |
| R-Squared | 0.71 | |
| Significance | 0.000023 | |
| Slope | (13,588,644) | |
| Total Sum of Squares | 106316.9T |
Rxsight Net Income History
Other Fundumenentals of Rxsight
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Rxsight Net Income component correlations
Rxsight Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Rxsight is extremely important. It helps to project a fair market value of Rxsight Stock properly, considering its historical fundamentals such as Net Income. Since Rxsight's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rxsight's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rxsight's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Health Care Equipment & Supplies market expansion? Will Rxsight introduce new products? Factors like these will boost the valuation of Rxsight. Anticipated expansion of Rxsight directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Rxsight listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.88) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets | Return On Equity |
Investors evaluate Rxsight using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Rxsight's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Rxsight's market price to deviate significantly from intrinsic value.
It's important to distinguish between Rxsight's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rxsight should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Rxsight's market price signifies the transaction level at which participants voluntarily complete trades.
Rxsight 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Rxsight's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Rxsight.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Rxsight on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Rxsight or generate 0.0% return on investment in Rxsight over 90 days. Rxsight is related to or competes with Neuropace, Tactile Systems, Orthopediatrics Corp, Butterfly Network, Treace Medical, DiaMedica Therapeutics, and Cerus. RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adj... More
Rxsight Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Rxsight's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Rxsight upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.59 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 23.38 | |||
| Value At Risk | (5.55) | |||
| Potential Upside | 7.97 |
Rxsight Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rxsight's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Rxsight's standard deviation. In reality, there are many statistical measures that can use Rxsight historical prices to predict the future Rxsight's volatility.| Risk Adjusted Performance | 0.0202 | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.39) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0271 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Rxsight's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Rxsight February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0202 | |||
| Market Risk Adjusted Performance | 0.0371 | |||
| Mean Deviation | 3.05 | |||
| Semi Deviation | 3.53 | |||
| Downside Deviation | 3.59 | |||
| Coefficient Of Variation | 6657.58 | |||
| Standard Deviation | 4.28 | |||
| Variance | 18.34 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.39) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0271 | |||
| Maximum Drawdown | 23.38 | |||
| Value At Risk | (5.55) | |||
| Potential Upside | 7.97 | |||
| Downside Variance | 12.86 | |||
| Semi Variance | 12.43 | |||
| Expected Short fall | (3.42) | |||
| Skewness | 0.9917 | |||
| Kurtosis | 2.27 |
Rxsight Backtested Returns
Rxsight maintains Sharpe Ratio (i.e., Efficiency) of -0.042, which implies the firm had a -0.042 % return per unit of risk over the last 3 months. Rxsight exposes twenty-eight different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Rxsight's Risk Adjusted Performance of 0.0202, coefficient of variation of 6657.58, and Semi Deviation of 3.53 to confirm the risk estimate we provide. The company holds a Beta of 2.0, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rxsight will likely underperform. At this point, Rxsight has a negative expected return of -0.17%. Please make sure to check Rxsight's total risk alpha, downside variance, as well as the relationship between the Downside Variance and daily balance of power , to decide if Rxsight performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.49 |
Modest reverse predictability
Rxsight has modest reverse predictability. Overlapping area represents the amount of predictability between Rxsight time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Rxsight price movement. The serial correlation of -0.49 indicates that about 49.0% of current Rxsight price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.49 | |
| Spearman Rank Test | -0.56 | |
| Residual Average | 0.0 | |
| Price Variance | 0.68 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Rxsight Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Rxsight reported net income of (27.45 Million). This is 108.04% lower than that of the Health Care Equipment & Supplies sector and 111.53% lower than that of the Health Care industry. The net income for all United States stocks is 104.81% higher than that of the company.
Rxsight Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rxsight's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rxsight could also be used in its relative valuation, which is a method of valuing Rxsight by comparing valuation metrics of similar companies.Rxsight is currently under evaluation in net income category among its peers.
Rxsight ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rxsight's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rxsight's managers, analysts, and investors.Environmental | Governance | Social |
Rxsight Institutional Holders
Institutional Holdings refers to the ownership stake in Rxsight that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Rxsight's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Rxsight's value.| Shares | State Street Corp | 2025-06-30 | 916.2 K | Deerfield Management Co | 2025-06-30 | 889 K | Geode Capital Management, Llc | 2025-06-30 | 862.7 K | Crédit Agricole S.a. | 2025-03-31 | 786.1 K | Wellington Management Company Llp | 2025-06-30 | 728 K | Parkman Healthcare Partners Llc | 2025-06-30 | 633.9 K | Royal Bank Of Canada | 2025-06-30 | 529.2 K | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 481.1 K | Baillie Gifford & Co Limited. | 2025-06-30 | 468.9 K | Ra Capital Management, Llc | 2025-06-30 | 3.7 M | Blackrock Inc | 2025-06-30 | 3 M |
Rxsight Fundamentals
| Return On Equity | -0.13 | ||||
| Return On Asset | -0.0919 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 123.67 M | ||||
| Shares Outstanding | 41.12 M | ||||
| Shares Owned By Insiders | 5.62 % | ||||
| Shares Owned By Institutions | 82.80 % | ||||
| Number Of Shares Shorted | 4.78 M | ||||
| Price To Earning | 42.55 X | ||||
| Price To Book | 1.23 X | ||||
| Price To Sales | 2.39 X | ||||
| Revenue | 139.93 M | ||||
| Gross Profit | 106.53 M | ||||
| EBITDA | (23.76 M) | ||||
| Net Income | (27.45 M) | ||||
| Cash And Equivalents | 128.62 M | ||||
| Cash Per Share | 4.65 X | ||||
| Total Debt | 12.3 M | ||||
| Debt To Equity | 0.41 % | ||||
| Current Ratio | 11.54 X | ||||
| Book Value Per Share | 6.72 X | ||||
| Cash Flow From Operations | (16.95 M) | ||||
| Short Ratio | 5.51 X | ||||
| Earnings Per Share | (0.88) X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 10.39 | ||||
| Number Of Employees | 498 | ||||
| Beta | 1.13 | ||||
| Market Capitalization | 339.62 M | ||||
| Total Asset | 318.56 M | ||||
| Retained Earnings | (622.1 M) | ||||
| Working Capital | 267.95 M | ||||
| Net Asset | 318.56 M |
About Rxsight Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rxsight's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rxsight using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rxsight based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Rxsight Stock Analysis
When running Rxsight's price analysis, check to measure Rxsight's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rxsight is operating at the current time. Most of Rxsight's value examination focuses on studying past and present price action to predict the probability of Rxsight's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rxsight's price. Additionally, you may evaluate how the addition of Rxsight to your portfolios can decrease your overall portfolio volatility.